Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis
dc.contributor.author | Lai, T. | |
dc.contributor.author | Wang, Shaobin | |
dc.contributor.author | Xu, Z. | |
dc.contributor.author | Zhang, C. | |
dc.contributor.author | Zhao, Y. | |
dc.contributor.author | Hu, Y. | |
dc.contributor.author | Cao, C. | |
dc.contributor.author | Ying, S. | |
dc.contributor.author | Chen, Z. | |
dc.contributor.author | Li, W. | |
dc.contributor.author | Wu, B. | |
dc.contributor.author | Shen, H. | |
dc.date.accessioned | 2017-08-24T02:18:56Z | |
dc.date.available | 2017-08-24T02:18:56Z | |
dc.date.created | 2017-08-23T07:21:39Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Lai, T. and Wang, S. and Xu, Z. and Zhang, C. and Zhao, Y. and Hu, Y. and Cao, C. et al. 2015. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis. Scientific Reports. 5. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/55515 | |
dc.identifier.doi | 10.1038/srep08191 | |
dc.description.abstract |
Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs 52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma. | |
dc.publisher | Nature Publishing Group | |
dc.title | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis | |
dc.type | Journal Article | |
dcterms.source.volume | 5 | |
dcterms.source.issn | 2045-2322 | |
dcterms.source.title | Scientific Reports | |
curtin.department | Department of Chemical Engineering | |
curtin.accessStatus | Open access via publisher |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |